Close Menu

Cellestis

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen today said that it has completed the acquisition of all of the ordinary shares of Melbourne, Australia-based Cellestis for A$3.80 (US$4.04) per share.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.

Shareholders overwhelmingly approved an amended proposal that will result in Qiagen paying around $374 million to acquire the Australian firm.

Qiagen's offer represents a premium of roughly 41 percent premium to the three-month volume-weighted average price of Cellestis' shares ending on April 1.

With the help of QuantiFeron tests in the first-line setting, Qiagen is hoping to improve the capabilities of its DNA and RNA diagnostics in preventing and profiling disease and delivering personalized care.

The deal provides Qiagen with access to Cellestis' QuantiFeron "pre-molecular" testing technology for detecting and monitoring disease.

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan is to release rules governing some gene-edited food, according to NHK World.

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.